Top

Published in:

Open Access 01-12-2015 | Letter to the Editor

Upregulated TCRζ improves cytokine secretion in T cells from patients with AML

Authors: Shaohua Chen, Xianfeng Zha, Li Shi, Lingling Zhou, Lijian Yang, Bo Li, Xiuli Wu, Jun Zhong, Tao Zhang, Yuhong Lu, Kanger Zhu, Yangqiu Li

Published in: Journal of Hematology & Oncology | Issue 1/2015

Abstract

Previous studies indicated that upregulating TCRζ partially recovers T cell function in patients with leukemia. In this study, we characterized the cytokine profile of TCRζ-transfected T cells from acute myeloid leukemia (AML) patients by Quantibody®Array Glass Chip. Firstly, the significantly lower expression of TCRζ in CD3⁺/TCRζ⁺ cells from AML patients was found. Increased secretion of IL-2, IL-8, IL-10, IL-13, IFN-γ, TNF-α, GM-CSF, growth-regulated oncogene (GRO), MIP-1b, and regulated on activation, normal T cell expressed and secreted (RANTES) could be detected in T cells from AML patients after TCRζ upregulating. We concluded that upregulating TCRζ in T cells from AML can alter the secretion profile of cytokines and chemokine which are involved in T cell proliferation and activation.

Available only for authorised users

Löwenberg B. Prognostic factors in acute myeloid leukaemia. Best Pract Res ClinHaematol. 2001;14:65–75.CrossRef

Pleyer L, Stauder R, Burgstaller S, Schreder M, Tinchon C, Pfeilstocker M, et al. Azacitidine in patients with WHO-defined AML—results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. J HematolOncol. 2013;6:32.

van der Helm LH, Scheepers ER, Veeger NJ, Daenen SM, Mulder AB, van den Berg E, et al. Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients. J Hematol Oncol. 2013;6:29.PubMedCentralPubMedCrossRef

Shi L, Chen S, Zha X, Xu Y, Xu L, Yang L, et al. Enhancement of the TCRζ expression, polyclonal expansion and activation of T cells from patients with AML after IL-2, IL-7 and IL-12 induction. DNA Cell Biol. 2015 Mar 10. [Epub ahead of print]

Li Y. Alterations in the expression pattern of TCR zeta chain in T cells from patients with hematological diseases. Hematology. 2008;13:267–75.PubMedCrossRef

Chen X, Woiciechowsky A, Raffegerst S, Schendel D, Kolb HJ, Roskrow M. Impaired expression of the CD3-zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis. Br J Haematol. 2000;111:817–25.PubMed

Chen S, Yang L, Chen S, Li Y. TCR ζ chain expression in T cells from patients with CML. Hematology. 2009;14:95–100.PubMedCrossRef

Huang L, Chen S, Zha X, Yang L, Li B, Yu Z, et al. Expression feature of CD3, FcεRIγ and Zap-70 in patients with chronic lymphocytic leukemia. Hematology. 2012;17:71–5.PubMedCrossRef

Zha X, Chen S, Yang L, Shi L, Li B, Wu X, et al. Up-regulated TCRζ enhances interleukin-2 production in T-cells from patients with CML. DNA Cell Biol. 2012;31:1628–35.PubMedCentralPubMedCrossRef

10.

Nambiar MP, Fisher CU, Warke VG, Krishnan S, Mitchell JP, Delaney N, et al. Reconstitution of deficient T cell receptor zeta chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with systemic lupus erythematosus. Arthritis Rheum. 2003;48:1948–55.PubMedCrossRef

11.

Kaufman HL, Ruby CE, Hughes T, Slingluff Jr CL. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer. 2014;2:11.PubMedCentralPubMedCrossRef

12.

Xuan L, Wu X, Zhang Y, Fan Z, Ling Y, Huang F, et al. Granulocyte colony-stimulating factor affects the distribution and clonality of TRGV and TRDV repertoire of T cells and graft-versus-host disease. J Transl Med. 2011;9:215.PubMedCentralPubMedCrossRef

Title: Upregulated TCRζ improves cytokine secretion in T cells from patients with AML
Authors: Shaohua Chen
Xianfeng Zha
Li Shi
Lingling Zhou
Lijian Yang
Bo Li
Xiuli Wu
Jun Zhong
Tao Zhang
Yuhong Lu
Kanger Zhu
Yangqiu Li
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue 1/2015
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/s13045-015-0170-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

Alteration of gene expression profile following PPP2R5C knockdown may be associated with proliferation suppression and increased apoptosis of K562 cells

Journal of Hematology & Oncology reviewer acknowledgement 2014

Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients

Hematology research output from Chinese authors and other countries: a 10-year survey of the literature

Local administration of a novel Toll-like receptor 7 agonist in combination with doxorubicin induces durable tumouricidal effects in a murine model of T cell lymphoma

Persistent androgen receptor addiction in castration-resistant prostate cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer